Medtronic received FDA clearance for its LigaSure RAS Maryland jaw device on the Hugo robotic-assisted surgery system, adding a vessel sealer used in more than 45 million procedures to its U.S. robotic instrument tray. Hugo remains cleared only for urologic procedures in the U.S., so the revenue impact depends on pending general and gynecologic indication expansions and hospital adoption.
Surgeons running Medtronic's Hugo robot in the U.S. can now seal vessels with the company's own energy device, after the FDA cleared the LigaSure RAS Maryland jaw instrument for the platform on Sept. 16 — the first time Medtronic's sealing technology, used in more than 45 million procedures across 65-plus countries, has been cleared for American robotic-assisted surgery.
"Vessel sealing sits at the center of how surgeons work through the most demanding moments of a procedure, and surgeons have trusted LigaSure to do it across open and laparoscopic surgery for decades," said Dr. Matthew Kroh, chief medical officer within the Surgical business at Medtronic and a practicing surgeon. "Bringing that same performance to the Hugo RAS system in the U.S. means surgeons carry the confidence and control they already rely on into their robotic-assisted cases."
The instrument seals and cuts vessels, thick tissue and lymphatics up to and including 7 millimeters in diameter, closing vessels in roughly 2 seconds while limiting thermal spread to surrounding tissue, according to Medtronic. It runs exclusively on the Valleylab FT10 energy platform inside the Hugo system. The device reached Europe in 2025 under CE Mark; the U.S. clearance arrives roughly a year later.
The commercial question is narrower than the headline. Hugo is cleared in the U.S. only for urologic procedures, and Medtronic says it is working to extend that to general and gynecologic surgery. Outside the U.S., the system has treated patients in more than 35 countries across more than 50 procedure types. Every instrument added to the U.S. tray widens what a hospital can justify buying — but the indication label, not the instrument count, sets the ceiling on revenue.
Robotic surgery economics run on consumables, not capital. Intuitive Surgical's da Vinci installed base reached more than 10,600 systems at the end of 2024, with instruments and accessories generating over $5 billion and service contracts another $1.3 billion — roughly three-quarters of total revenue, according to the company's 2024 annual report. Da Vinci systems have logged more than 17 million cumulative procedures, including about 2.7 million in 2024 alone, a 17% increase.
That is the gap Medtronic is attacking with a different instrument strategy. Hugo's four independent arm carts and open console are built for modularity and a smaller footprint than the monolithic da Vinci platform. Adding LigaSure matters because it removes a switching objection: a surgeon trained on LigaSure in laparoscopic cases does not have to learn a new sealing device to move to Hugo. Medtronic acquired that franchise with Covidien in 2015, and the brand carries two decades of procedural history.
The counterargument is data. Intuitive's da Vinci 5 captures synchronized video, kinematics and force feedback, and the company spent $1.145 billion on research and development in 2024. Medtronic's digital layer, Touch Surgery Enterprise, is a video analytics platform that segments procedures and anonymizes footage — useful for training and review, but shallower than a system that records what the surgeon's hands actually did. Medtronic did not disclose whether the LigaSure RAS instrument feeds any kinematic or energy-usage data back into Touch Surgery.
Medtronic is not the only challenger repositioning. Johnson & Johnson's Ottava robot holds an investigational device exemption and is paired with the Polyphonic digital ecosystem, built with Nvidia and AWS on an open, data-agnostic model. In orthopedics, Stryker's handheld Mako RPS completed its first U.S. case in January, and Smith+Nephew reported that 45% of new CORI systems in its full-year 2025 results went into ambulatory surgery centers — evidence that the next wave of robotic placements is being decided on footprint and per-case economics rather than clinical prestige alone.
For Medtronic, the near-term read is incremental rather than transformational. The company has not disclosed Hugo's U.S. installed base, procedure volumes, or the revenue contribution of the LigaSure RAS instrument, and no pricing has been published. Medtronic reports on a fiscal year ending in April, so any U.S. Hugo instrument revenue lands in fiscal 2027 results. The stock's reaction to the clearance was not yet disclosed at the time of publication.
What to watch is the indication label. A general surgery clearance would move Hugo from a urology niche into the largest soft-tissue categories, where LigaSure's familiarity carries the most weight. Until then, the instrument is a necessary building block rather than a revenue event — and the market will judge the franchise on placements, not clearances.
This article is for informational purposes only and does not constitute investment advice.
